Literature DB >> 21167123

Protein phosphatases: possible bisphosphonate binding sites mediating stimulation of osteoblast proliferation.

Susana Morelli1, Paola Scodelaro Bilbao, Sebastian Katz, Virginia Lezcano, Emilio Roldán, Ricardo Boland, Graciela Santillan.   

Abstract

We investigated the existence of a bisphosphonate (BP) target site in osteoblasts. Binding assays using [³H]-olpadronate ([³H]OPD) in whole cells showed the presence of specific, saturable and high affinity binding for OPD (K(d)=1.39 ± 0.33 μM) in osteoblasts. [³H]OPD was displaced from its binding site by micromolar concentrations of lidadronate, alendronate and etidronate (K(d)=1.42 ± 0.15 μM, 2.00 ± 0.2 μM and 2.4 ± 0.4 μM, respectively), and by millimolar concentrations of the non-permeant protein phosphatase (PP) substrates p-nitrophenylphosphate and α-naphtylphosphate. PP inhibitors orthovanadate, NaF or vpb(bipy) did not displace [³H]OPD. As expected, specific OPD binding was detected in the plasma membrane of ROS 17/2.8 cells, although significant BP binding was also found intracellularly. Moreover, OPD increased DNA synthesis in these cells with a temporal profile similar to the protein tyrosine phosphatase (PTP) inhibitors, Na₃VO₄ and vpb(bipy); but different from a general PP inhibitor (NaF). The stimulatory effect of OPD and PTP inhibitors on osteoblast proliferation was inhibited by the protein tyrosine kinase inhibitors genistein and geldanamycin. These results provide new evidence on the existence of a BP target in osteoblastic cells, presumably a PTP, which may be involved in the stimulatory action of BPs on osteoblast proliferation.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21167123     DOI: 10.1016/j.abb.2010.12.013

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  8 in total

1.  Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways.

Authors:  V Lezcano; T Bellido; L I Plotkin; R Boland; S Morelli
Journal:  Arch Biochem Biophys       Date:  2012-01-03       Impact factor: 4.013

Review 2.  Beyond gap junctions: Connexin43 and bone cell signaling.

Authors:  Lilian I Plotkin; Teresita Bellido
Journal:  Bone       Date:  2012-10-02       Impact factor: 4.398

3.  Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate.

Authors:  V Lezcano; T Bellido; L I Plotkin; R Boland; S Morelli
Journal:  Exp Cell Res       Date:  2014-03-31       Impact factor: 3.905

4.  Long-term Treatment with Oriental Medicinal Herb Artemisia princeps Alters Neuroplasticity in a Rat Model of Ovarian Hormone Deficiency.

Authors:  Hyun-Bum Kim; Byeong-Jae Kwon; Hyun-Ji Cho; Ji-Won Kim; Jeong-Woo Chon; Moon-Ho Do; Sang-Yong Park; Sun-Yeou Kim; Sung-Ho Maeng; Yoo-Kyoung Park; Ji-Ho Park
Journal:  Exp Neurobiol       Date:  2015-02-17       Impact factor: 3.261

5.  Positive impact of Platelet-rich plasma and Platelet-rich fibrin on viability, migration and proliferation of osteoblasts and fibroblasts treated with zoledronic acid.

Authors:  Daniel Steller; Nele Herbst; Ralph Pries; David Juhl; Samer G Hakim
Journal:  Sci Rep       Date:  2019-06-05       Impact factor: 4.379

Review 6.  Protein tyrosine phosphatases in skeletal development and diseases.

Authors:  Huiliang Yang; Lijun Wang; Christian Shigley; Wentian Yang
Journal:  Bone Res       Date:  2022-01-28       Impact factor: 13.567

Review 7.  Connexin 43 hemichannels and intracellular signaling in bone cells.

Authors:  Lilian I Plotkin
Journal:  Front Physiol       Date:  2014-04-04       Impact factor: 4.566

8.  Engineered Nanomedicine with Alendronic Acid Corona Improves Targeting to Osteosarcoma.

Authors:  Tuyen Duong Thanh Nguyen; Arunkumar Pitchaimani; Santosh Aryal
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.